Literature DB >> 21400521

Contiguous organ resection is safe in patients with retroperitoneal sarcoma: An ACS-NSQIP analysis.

Warren H Tseng1, Steve R Martinez, Robert M Tamurian, Steven L Chen, Richard J Bold, Robert J Canter.   

Abstract

BACKGROUND AND OBJECTIVES: The practice of aggressive contiguous organ resection (COR) of retroperitoneal sarcoma (RPS) is controversial. We examined rates of 30-day morbidity and mortality following resection of RPS utilizing data from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database.
METHODS: From 2005 to 2007, we identified 156 cases of primary malignant neoplasm of the retroperitoneum. Univariate and multivariate analyses were performed using all pre-operative ACS-NSQIP variables for likelihood of post-operative overall morbidity or severe morbidity (composite endpoint including organ space infection, septic shock, acute renal failure requiring dialysis, reoperation, and death). Insufficient events precluded multivariate analysis of mortality as an independent outcome.
RESULTS: Overall 30-day morbidity, severe morbidity, and mortality were 26% (N = 40), 11.5% (N = 18), and 1.3% (N = 2), respectively. Fifty-eight patients (37%) underwent COR, most commonly kidney. American Society for Anesthesiologists classification predicted overall morbidity (OR 3.23, 95% CI 1.33-7.84), while increasing operative time predicted severe morbidity (OR 1.38 per hour, 95% CI 1.05-1.81). COR was not associated with increased 30-day overall morbidity (OR 1.38, 95% CI 0.49-3.89) or severe morbidity (OR 0.78, 95% CI 0.05-13.18).
CONCLUSIONS: Rates of post-operative morbidity and mortality are acceptable following RPS resection, even in the setting of multi-visceral resection. COR should not be viewed as a contraindication to complete RPS resection.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 21400521     DOI: 10.1002/jso.21849

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  15 in total

1.  Long-term results of primary and secondary resections in patients with retroperitoneal soft tissue sarcoma.

Authors:  Alexandra M Koenig; Matthias Reeh; Christoph M Burdelski; Claudia Wengert; Karim A Gawad; Jakob R Izbicki; Maximilian Bockhorn
Journal:  Langenbecks Arch Surg       Date:  2012-03-10       Impact factor: 3.445

2.  The modified frailty index to predict morbidity and mortality for retroperitoneal sarcoma resections.

Authors:  Jiwon Sarah Park; Sarah B Bateni; Richard J Bold; Amanda R Kirane; Daniel J Canter; Robert J Canter
Journal:  J Surg Res       Date:  2017-05-11       Impact factor: 2.192

3.  Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study.

Authors:  Martin K Angele; Markus Albertsmeier; Niclas J Prix; Peter Hohenberger; Sultan Abdel-Rahman; Nelli Dieterle; Michael Schmidt; Ulrich Mansmann; Christiane J Bruns; Rolf D Issels; Karl-Walter Jauch; Lars H Lindner
Journal:  Ann Surg       Date:  2014-11       Impact factor: 12.969

4.  National Trends in Treatment for Retroperitoneal Soft Tissue Sarcoma: A Modern Appraisal of Variability in Therapeutic Strategies.

Authors:  Anthony M Villano; Roberto J Vidri; Elaine T Vo; Stephanie H Greco; Krisha J Howell; Margaret von Mehren; Jeffrey M Farma
Journal:  Ann Surg Oncol       Date:  2021-10-11       Impact factor: 5.344

5.  Complete and safe resection of challenging retroperitoneal tumors: anticipation of multi-organ and major vascular resection and use of adjunct procedures.

Authors:  William W Tseng; Sam C Wang; Charles M Eichler; Robert S Warren; Eric K Nakakura
Journal:  World J Surg Oncol       Date:  2011-11-04       Impact factor: 2.754

6.  Inferior vena cava resection and reconstruction with a peritoneal patch for a leiomyosarcoma: A case report.

Authors:  Matteo Risaliti; Laura Fortuna; Ilenia Bartolini; Antonio Taddei; Paolo Muiesan
Journal:  Int J Surg Case Rep       Date:  2020-05-08

7.  Clinical experience with the treatment of retroperitoneal vascular leiomyosarcoma originating from large veins.

Authors:  Hong-Xian Zhang; Kai Wang; Peng Hong; Min Lu; Zhuo Liu; Lei Liu; Guo-Liang Wang; Lu-Lin Ma
Journal:  BMC Surg       Date:  2021-08-15       Impact factor: 2.102

8.  Renal Function After Retroperitoneal Sarcoma Resection with Nephrectomy: A Matched Analysis of the United States Sarcoma Collaborative Database.

Authors:  Christopher C Stahl; Patrick B Schwartz; Cecilia G Ethun; Nicholas Marka; Bradley A Krasnick; Thuy B Tran; George A Poultsides; Kevin K Roggin; Ryan C Fields; Callisia N Clarke; Konstantinos I Votanopoulos; Kenneth Cardona; Daniel E Abbott
Journal:  Ann Surg Oncol       Date:  2020-11-04       Impact factor: 5.344

9.  Thirty-Day Outcomes after Surgery for Primary Sarcomas of the Extremities: An Analysis of the NSQIP Database.

Authors:  Kathryn E Gallaway; Junho Ahn; Alexandra K Callan
Journal:  J Oncol       Date:  2020-01-13       Impact factor: 4.375

10.  Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma.

Authors:  Makito Miyake; Yuki Oda; Nobutaka Nishimura; Yosuke Morizawa; Sayuri Ohnishi; Kinta Hatakeyama; Tomomi Fujii; Shunta Hori; Daisuke Gotoh; Yasushi Nakai; Satoshi Anai; Kazumasa Torimoto; Shinji Tsukamoto; Hiromasa Fujii; Akira Kido; Kanya Honoki; Yoshiaki Matsumura; Eijiro Okajima; Nobumichi Tanaka; Kiyohide Fujimoto
Journal:  Oncol Lett       Date:  2020-09-03       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.